Status:
UNKNOWN
The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Fondazione Ricerca Traslazionale
Conditions:
To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods
Eligibility:
All Genders
18-90 years
Brief Summary
This retrospective study explores the combination of Programmed cell death ligand 1 (PD-L1) expression and Neutrophil to Lymphocyte Ratio (NLR) as an easy feasible panel to predict benefit to nivoluma...
Detailed Description
We will retrospectively analyze patients with advanced NSCLC who have received at least one cycle of nivolumab (3mg/kg intravenously every 2 weeks) within the early access program (EAP) or after the d...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with histologic diagnosis of advanced NSCLC who received Nivolumab as second or further line of therapy
- Paraffin-embedded tissue sample available for PD-L1 analysis
- disponibilità di emocromo entro 4 settimane dall'inizio del trattamento con Nivolumab
- To calculate NLR, the absolute neutrophil count was divided by the lymphocytes value measured in peripheral blood within 4 weeks prior to the first infusion of nivolumab.
- No main Exclusion Criteria
Exclusion
Key Trial Info
Start Date :
February 15 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2019
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT03816657
Start Date
February 15 2015
End Date
March 30 2019
Last Update
January 25 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.